My previous reply was to Ymav. FYI. Missed Andrew's post.
Completely agree Andrew. Though I expect it possible in CVac's case, the FDA would approve based on PFS alone (fast track), as there is little risk to the patient.
Avastin's approval for breast cancer was revoked primarily because the risks outweighed the benefit.
This is where I went off-track with my incredulity in my above post - EMA vs FDA.
My previous reply was to Ymav. FYI. Missed Andrew's...
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.5¢ |
Change
0.015(5.36%) |
Mkt cap ! $428.5M | |||
| Open | High | Low | Value | Volume |
| 28.5¢ | 30.5¢ | 28.0¢ | $833.4K | 2.824M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 388130 | 29.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.0¢ | 39940 | 3 |
View Market Depth
| Last trade - 16.10pm 05/07/2024 (20 minute delay) ? |
| IMM (ASX) Chart |